What were the results of the two trials regarding rosuvastatin and chronic heart failure?
The two trials, CORONA and GISSI-HF, revealed that treatment with rosuvastatin did not confer significant clinical benefit in patients with chronic heart failure of either ischemic or nonischemic origin. Despite retrospective analyses and small trials demonstrating beneficial effects of statins in patients with heart failure, the two large trials did not show any significant difference between the rosuvastatin- and placebo-treated patients in terms of primary and secondary end points, such as death resulting from cardiovascular causes, nonfatal MI, or nonfatal stroke, all-cause mortality, coronary events, and worsening HF.